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Abstract
Background: Multivariate assays (MVAs) for assisting clinical decisions are becoming commonly available, but due
to complexity, are often considered a high-risk approach. A key concern is that uncertainty on the assay’s final
results is not well understood. This study focuses on developing a process to characterize error introduced in the
MVA’s results from the intrinsic error in the laboratory process: sample preparation and measurement of the
contributing factors, such as gene expression.
Methods: Using the PAM50 Breast Cancer Intrinsic Classifier, we show how to characterize error within an MVA,
and how these errors may affect results reported to clinicians. First we estimated the error distribution for
measured factors within the PAM50 assay by performing repeated measures on four archetypal samples
representative of the major breast cancer tumor subtypes. Then, using the error distributions and the original
archetypal sample data, we used Monte Carlo simulations to generate a sufficient number of simulated samples.
The effect of these errors on the PAM50 tumor subtype classification was estimated by measuring subtype
reproducibility after classifying all simulated samples. Subtype reproducibility was measured as the percentage of
simulated samples classified identically to the parent sample. The simulation was thereafter repeated on a large,
independent data set of samples from the GEICAM 9906 clinical trial. Simulated samples from the GEICAM sample
set were used to explore a more realistic scenario where, unlike archetypal samples, many samples are not easily
classified.
Results: All simulated samples derived from the archetypal samples were classified identically to the parent
sample. Subtypes for simulated samples from the GEICAM set were also highly reproducible, but there were a non-
negligible number of samples that exhibit significant variability in their classification.
Conclusions: We have developed a general methodology to estimate the effects of intrinsic errors within MVAs.
We have applied the method to the PAM50 assay, showing that the PAM50 results are resilient to intrinsic errors
within the assay, but also finding that in non-archetypal samples, experimental errors can lead to quite different
classification of a tumor. Finally we propose a way to provide the uncertainty information in a usable way for
clinicians.
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Multivariate assays (MVAs) using gene expression as
their contributing factors are becoming commonly used
in assisting treatment decisions in medicine, especially
in oncology. Examples of MVAs available for planning
breast cancer treatment include the 55-gene subtype
classifier (PAM50 Breast Cancer Intrinsic Classifier) [1],
the 21-gene prognosis assay (Oncotype DX
®)[ 2 ] ,t h e
1 4 - g e n ep r o g n o s i sa s s a y( B r e a s t O n c P x ™)[ 3 ]a n dt h e
70-gene prognosis assay (MammaPrint
®)[ 4 ] .T h o u g h
physicians may rely on these MVAs for planning treat-
m e n t ,l i t t l ei sk n o w na b o u tt h ee f f e c t so nt h er e s u l t so f
an assay due to the intrinsic error in the laboratory pro-
cess and measuring its contributing factors - in this
case, all steps required for preparing a sample (post
RNA extraction), preparing t h ea s s a y ,a n dt h ei n s t r u -
mental errors for measuring gene expression. While we
expect that classification of samples in proximity to one
of the centroids defining the tumor classes, which we
will call archetypal samples here, will be very stable with
respect to experimental errors in the gene expression
measurements, what happens to the samples not in
proximity to one centroid is unknown. For example, if a
sample lies in a “gray” area where the intrinsic errors in
the gene expression measurements may result in a
change of its classification each time the sample is run,
the results reported to the attending physician may be
misleading because he/she is getting the results from
only one measurement and no information about the
probability for sample misclassification. Given the ser-
ious consequences due to ambiguous results in clinical
classifications, methods to measure the effects of an
MVA’s intrinsic errors need to be established and com-
municated to attending physicians.
The PAM50 assay measures the expression level of 55
genes (50 classifier genes and 5 housekeepers) creating a
“signature” that is compared, using Spearman’s Rho as a
distance measure, to each of five centroids [1,5] repre-
senting the Luminal A, Luminal B, HER2-enriched and
Basal-like subtypes [1,6,7], as well as Normal-like tissue.
The complexity of the PAM50 assay demonstrates the
challenge of identifying and understanding error sources
from the moment a sample is received by the reference
laboratory until a clinical report is generated. Error
sources to be considered include heterogeneity and sam-
ple preparation, as well as technical variability, which
may be separated into error from measuring devices as
well as intrinsic and explicit classification uncertainties.
While the overall purpose of this project is to develop a
model for estimating the effect of all error sources on
final MVA results, in this paper we focus on how to esti-
mate the effect that intrinsic gene expression measure-
ment errors, including those associated with sample and
assay preparation, have on the classification of tumors.
Methods
A comprehensive experimental study to estimate the
effect that the intrinsic gene expression measurement
errors have on the classification of tumors and gene-
score classifications requires, in principle, repeated test-
ing of a significant number of samples from each sub-
type and thorough analysis of the misclassifications
observed. Such a comprehensive approach is unfeasible
in terms of cost and sample availability. Here we have
adopted a hybrid approach in which we perform
repeated experimental measurements on one sample
from each subtype (i.e. Luminal A, Luminal B, HER2-
enriched and Basal-like) to determine the experimental
variability of the measured gene expression for each of
the 50 genes included in the PAM50 assay. Using this
experimental information we proceed to generate a
Gaussian error distribution that can be used to generate
multiple data sets by way of Monte Carlo simulations.
These simulations impose random errors, given by the
Gaussian distribution, on the set of experimental mea-
sured samples. Monte Carlo simulations are well suited
for this hybrid analysis because there is extensive litera-
ture for using this approach to estimate errors in high-
dimensional problems, such as fluids and thermody-
namics [8-10], where conventional analytics are not fea-
sible [11,12]. The simulated data sets are then classified
by the standard PAM50 algorithm, and the misclassifica-
tions encountered in the synthetic data sets are used as
a proxy for the PAM50’s misclassification rate based on
the assay’s intrinsic error.
Specifically, in this study we followed five major steps:
(1) collect and prepare four archetypal samples repre-
sentative of each cancer subtype; (2) characterize the
intrinsic error for each gene’se x p r e s s i o nv a l u e si nt h e
assay by making twelve measurements for each gene’s
expression on each archetypal sample and determine the
distribution type that best models the experimental
errors; (3) using Monte Carlo simulations generate a
sufficient number of simulated test samples, based on a
defined confidence interval width, by imposing the
errors generated using the distribution from (2) onto
the archetypal samples; (4) determine the effect of the
variability imposed in the simulated samples on their
classification; and (5) repeat steps (3) and (4) on an
independent set of samples from the GEICAM 9906
clinical trial (GEICAM) [13].
Archetypal Sample Collection and Preparation
In order to characterize the error in gene expression
measurements, four archetypal samples representative of
each cancer subtype with sufficient genetic material
were constructed - since most single samples do not
have enough genetic material to be tested more than
twice. Cell lines representative of Basal-like (ME16C)
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Reagent Lab at ARUP Laboratories. Luminal A and
HER2-enriched subtypes were not readily available as a
cell lines. As such, 20 patient tumor samples previously
identified as archetypal Luminal A (10 samples) and
HER2-enriched (10 samples), based on PAM50 gene
scores and classification, were collected under IRB
approved protocols at the University of Utah to be com-
bined and treated as single tumor samples.
RNA was extracted from tumor-enriched areas of for-
malin-fixed, paraffin-embedded (FFPE) tissue blocks,
containing more than 70% tumor cells, as determined
during review by a board-certified pathologist. Samples
were deparaffinized using Citrus Clearing Solvent
(Richard-Allen Scientific, Kalamazoo, MI, http://www.
thermofisher.com) followed by dehydration in absolute
ethanol. RNA extraction was completed on a Biomek
NX Laboratory Automation Workstation (Beckman
Coulter, Beverly, MA, http://www.beckmancoulter.com)
using the AgenCourt FormaPure Kit (Beckman Coulter,
Beverly, MA, http://www.beckmancoulter.com) accord-
ing to the manufacturer’si n s t r u c t i o n sa n di n c l u d i n ga
DNase I step. RNA quantification was done on a Para-
digm Detection Platform (Beckman Coulter, Beverly,
MA, http://www.beckmancoulter.com) using the Quant-
iT RiboGreen Assay Kit (Invitrogen, Carlsbad, CA,
http://www.invitrogen.com). cDNA synthesis was per-
formed on the Biomek FX Laboratory Automation
Workstation (Beckman Coulter, Beverly, MA, http://
www.beckmancoulter.com) using 600 ng of RNA, uracil
containing dNTPs (Invitrogen, Carlsbad, CA, http://
www.invitrogen.com), random primers (Invitrogen,
Carlsbad, CA, http://www.invitrogen.com), gene-specific,
downstream PCR primers (Idaho Technology, Salt Lake
City, UT, http://www.idahotech.com ), and SuperScript
III Reverse Transcriptase (Invitrogen, Carlsbad, CA,
http://www.invitrogen.com ).
Each 5 μL reaction contained 1X LightCycler 480
SYBR Green I Master Mix (Roche Applied Sciences,
Indianapolis, IN, http://www.roche-applied-science.com)
and 1.67 ng cDNA were added to the experimental sam-
ple wells. Sample cDNA was incubated with LightCycler
Uracil-DNA Glycosylase (Roche Applied Sciences, India-
napolis, IN, http://www.roche-applied-science.com) at
40°C for 10 min and inactivated at 95°C for 10 min
prior to performing Real-time, quantitative PCR (RT-
qPCR). RT-qPCR was performed on the LightCycler
(LC) 480 (Roche Applied Sciences, Indianapolis, IN,
http://www.roche-applied-science.com) as follows: 45
cycles at 95°C for 4 sec, 58°C for 6 sec and 72°C for 6
sec. To assure target specificity, RT-qPCR was followed
b yam e l t i n gc u r v ea n a l y s i s :9 5 ° Cf o r1 5s e c ,6 5 ° Cf o r1
min followed by raising the temperature to 99°C while
taking 10 fluorescence acquisitions/°C. We then
classified the RT-qPCR data from each run. One run
from the Luminal A sample failed quality control and
was not included in further analysis.
Error Characterization
In order to estimate the intrinsic experimental error in
gene expression measurements within our laboratory,
we performed twelve measurements for each gene on
each archetypal sample. Each of the four archetypal
samples was separated into, and treated as, twelve indi-
vidual samples, and measured by RT-qPCR on the
Roche LightCycler (LC) 480 (Roche Applied Sciences,
Indianapolis, IN, http://www.roche-applied-science.com).
The error distribution function type could not be esti-
mated using only the twelve measurements for each
gene within a given sample subtype, therefore to deter-
mine the error distribution function type for each gene,
all four sample subtypes were median-centered by gene
and combined, giving forty-seven data points per gene,
since one of the archetypal Luminal A samples failed
quality control. As depicted in Figure 1, the resultant
error distributions for each gene can be reasonably
approximated by Gaussian distributions. Therefore two
hundred Gaussian distributions were generated, one per
gene within each archetypal sample, using the mean and
standard deviation of the twelve data points within the
given gene and archetypal sample. Note that only the
twelve data points available for each gene were used to
determine the mean and standard deviation because the
mean and standard deviation must be specific to the
gene and subtype, whereas all forty-seven data points
per gene were necessary to form a recognizable distribu-
tion. Gaussian distributions were generated using the
“rnorm” function within The R Statistical Package (R)
[14].
Sample Size Justification for Archetypal Sample Monte
Carlo Simulation
Before performing the Monte Carlo simulations an ana-
lysis to justify sample size was performed to ensure suf-
ficient confidence for the analysis when using our target
of 100,000 simulated samples. We calculated the 95%
confidence interval width around the percentage of cor-
rect classifications using 100,000 simulated samples for
each archetypal sample. For a dichotomous variable (i.e.
misclassified or not), a confidence interval width (W)
can be calculated (Eq. 1) given an alpha
W = ±Zα

θ(1 − θ)
π
(1)
level (Z0.05 = 1.96), expected proportion of misclassifi-
cations (θ = 0.02) and the sample size, or in this case,
the number of simulations (n = 100,000). The calculated
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tion of 100,000 samples, which is an acceptable value.
Monte Carlo Simulation Using Archetypal Samples
Monte Carlo simulations were performed using the
mean (μ) value and standard deviation (s)f o rt h e
expression of each gene within the archetypal samples,
as described above. This procedure created a total of
two hundred independent distributions, i.e. fifty Gaus-
sian distributions (one for each gene) for each of the
four archetypal samples. For example, the mean expres-
sion value (μ) for ACTR3B from the twelve Luminal B
values was 1.94 and the corresponding standard devia-
tion (s) was 0.085. Therefore the ACTR3B expression
value for each of the 100,000 simulated Luminal B sam-
ples was randomly selected from a Gaussian distribution
centered on a mean (μ) of 1.94 and with a standard
deviation (s) of 0.085. Randomly selecting a value from
the Gaussian distribution, as described, does not assume
gene expression values are independent of one another,
rather the method assumes that the measurement error
for each gene is independent. Specifically, since each
Gaussian distribution is centered on the gene’sm e a n
expression value for the given sample, any genes within
the sample that are generally upregulated will all be gen-
erally upregulated in the simulated samples, while allow-
ing the error to deviate independently. The 100,000
simulated samples for each archetypal sample were clas-
sified using the standard PAM50 process. The effect of
intrinsic gene expression measurement error on the
tumor classification was assessed by determining the
percentage of simulated samples that were classified
identically to the original sample. This value provides an
estimate of the reproducibility of the results for archety-
pal samples.
Evaluation Using the GEICAM Larger and Independent
Test Set
Testing archetypal samples is valuable for determining
how the PAM50 assay will perform under ideal circum-
stances, but these results may not be informative when
the samples are not as well characterized as the archety-
pal samples. Thus, the method described above for the
archetypal samples was adapted and applied to the lar-
ger and more diverse set of independent samples from
the GEICAM 9906 clinical trial. A total of 911 breast
tumors collected by the GEICAM group for the GEI-
CAM 9906 clinical trial were run and classified by the
PAM50. Tumor samples were prepared following the
same methods described above for the archetypal sam-
ples and those with insufficient tumor content to be
classified were excluded from further analyses.
Monte Carlo Simulation Using GEICAM Samples
As depicted in Figure 2, the data from the multiple mea-
surements in the archetypal samples show that standard
deviation depends on the relative average gene expres-
sion value and on the sample subtype. To understand
the sample subtype dependence one should understand
that the expression values of the genes defining the
expression pattern for each of the cancer subtype are
quite different, e.g. the Luminal A subtype expresses all
50 genes at a level that is more easily quantified, produ-
cing a lower standard deviation; however, the HER2-
enriched subtype expresses some genes at lower levels
such that they are less easily quantified, producing a
higher standard deviation. Therefore as depicted in
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Figure 1 Representative error distributions of the expression value used to fit the Gaussian distribution used in this work. A complete
set of the error distributions is given in Additional file 1.
Ebbert et al. Journal of Clinical Bioinformatics 2011, 1:37
http://www.jclinbioinformatics.com/content/1/1/37
Page 4 of 9Figure 2, the relative errors in the gene expression mea-
surements in a Luminal A sample are smaller than
those in a HER2-enriched sample. Accordingly our
methods to produce simulated samples have to be modi-
fied to take into account these dependencies when
applied to a set of non-archetypal samples. Using locally
weighted scatter plot smoothing (loess), based on the
PAM50’s characterized error functions depicted in Fig-
ure 2, we developed error distributions that can be used
to impose the error on individual test samples dynami-
cally. The loess model was fit using the R function
“loess” (span = 0.75, degree = 1, surface = “direct” and
family = “symmetric”)a n dg r a p h e du s i n g“panel.
smoother” from the R lattice graphics package. A 95%
confidence interval for the fitted line was also calculated
to test “best-case” (lower limit of the 95% confidence
interval), “worst-case” (upper limit of the 95% confi-
dence interval) and “average-case” (the fitted line) sce-
narios for subtype reproducibility. The “worst-case”
scenario is considered such because it uses the highest
estimated standard deviations, or error. Once the loess
models were developed, we used these models to predict
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tions for the Monte Carlo simulation. Specifically, given
the test sample’s original subtype and the expression
value for a given gene, we used the loess model to pre-
dict the standard deviation (s), or error, to be used in
the Gaussian distribution for said gene and sample. The
expression value was used as the mean of the Gaussian
distribution. We repeated this process for all genes
within each sample.
The model described above was used to generate ran-
dom variants of the 847 GEICAM samples remaining
after excluding those that could not be classified. The
subtype classification reproducibility for each GEICAM
sample was tested by generating 100,000 simulated sam-
ples using Monte Carlo simulations for each of the
error models considered above, i.e. “best-,”“ average-”
and “worst-case,” for a total of 300,000 simulated sam-
ples per GEICAM sample. Based on the same sample
justification analysis used for the archetypal samples, the
calculated confidence interval width is ± 0.00087 for
each simulation of 100,000 samples, which is an accep-
table value.
Error Effect on PAM50 Results for GEICAM Samples
After simulating 300,000 samples for each GEICAM
sample based on the error models described above, sub-
type reproducibility for the individual samples was sum-
marized for each tumor subtype (based on the original
sample’s subtype) using two statistics: (1) the total per-
centage of simulated samples that did (or did not)
change subtypes with respect to their parent sample and
(2) the proportion of simulated samples, corresponding
to a single original sample, that were classified (or mis-
classified) identically to the parent sample. These data
s e r v ea sa ne s t i m a t eo fP A M 5 0 ’s misclassification rate
based on intrinsic error within the assay when samples
are not in proximity to the PAM50 centroids.
Results and Discussion
Archetypal Samples
All simulated samples derived from the archetypal sam-
ples were classified the same subtype as the parent sam-
ple, indicating that the PAM50 subtype classification for
samples with characteristics close to the PAM50
centroids is highly reproducible and resilient to experi-
mental errors in gene expression measurements.
Although this positive result is encouraging for PAM50
classifications, it is not generalizable beyond the four
archetypal samples.
GEICAM 9906 Samples
Tables 1, 2, 3 present the results for the classification of
all the samples produced by Monte Carlo simulation
using the “best-” (Table 1), “average-” (Table 2) and
“worst-case” (Table 3) scenarios for the error models
described above. These scenarios correspond to using
the lower values of the 95% confidence interval for the
predicted error-model line, the actual predicted line and
the upper values of the 95% confidence interval, respec-
tively. The upper values of the 95% confidence interval
are representative of the “worst-case” scenario because a
greater amount of error is introduced into the
simulation.
Results for the GEICAM sample simulations suggest
that all subtype classes are highly reproducible. When
considering the three different error models, the most
reproducible subtype among all GEICAM samples was
always the Basal-like for which 98.47% (average-case) of
the simulated samples did not change classification, fol-
lowed by Luminal B (96.63%, average-case), Luminal A
(95.46%, average-case) and HER2-enriched (90.07%,
average-case). The differences in reproducibility between
“best-” and “worst-case” ("best-case” percentages minus
“worst-case” percentages) are 0.89%, 1.31%, 1.31% and
4.35% for Basal-like, Luminal B, Luminal A and HER2-
enriched, respectively. Therefore, the selection of the
error model is not a determining factor in assessing the
robustness of the classification due to experimental
errors in gene expression measurement.
Figure 3 presents the histograms depicting the percen-
tage of simulated samples, corresponding to a single
parent sample, that change. Based on the “average-case”
simulations and analyzing the classification of the
100,000 simulated samples generated for each sample
we found that 80% (68 of 85) of Basal-like samples
never change subtype during the Monte Carlo simula-
tion, 69% (186 of 270) of Luminal B samples never
change, 59% (178 of 303) of Luminal A samples never
Table 1 Original GEICAM Sample Subtype vs Simulated Sample Subtype (as Percentage) - Best-Case Scenario
Original Subtype
(simulated samples)
Classified as Subtype (%)
Luminal A Luminal B HER2-enriched Basal-like Normal-like
Luminal A (303000) 96.12 1.67 1.55 0 0.66
Luminal B (270000) 1.93 97.27 0.80 0 0
HER2-enriched (189000) 3.80 2.99 92.25 0.24 0.73
Basal-like (85000) 0 0 1.14 98.86 0
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Page 6 of 9Table 2 Original GEICAM Sample Subtype vs. Simulated Sample Subtype (as Percentage) - Average-Case Scenario
Original Subtype
(simulated samples)
Classified as Subtype (%)
Luminal A Luminal B HER2-enriched Basal-like Normal-like
Luminal A (303000) 95.46 1.98 1.74 0 0.81
Luminal B (270000) 2.34 96.63 1.03 0 0
HER2-enriched (189000) 4.69 3.76 90.07 0.45 1.03
Basal-like (85000) 0 0 1.51 98.47 0.02
Table 3 Original GEICAM Sample Subtype vs. Simulated Sample Subtype (as Percentage) - Worst-Case Scenario
Original Subtype
(simulated samples)
Classified as Subtype (%)
Luminal A Luminal B HER2-enriched Basal-like Normal-like
Luminal A (303000) 94.81 2.29 1.93 0 0.97
Luminal B (270000) 2.75 95.96 1.29 0 0
HER2-enriched (189000) 5.65 4.45 87.90 0.67 1.33
Basal-like (85000) 0 0.01 1.98 97.97 0.04
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Page 7 of 9change and 22% (42 of 189) of HER2-enriched samples
never change subtype. These values correspond approxi-
mately to the first bucket in the histogram. While the
histograms confirm the results from Tables 1, 2, 3 on
the general robustness of the PAM50 classification, they
a l s or e v e a lt h a tt h e r ea r ean o n - n e g l i g i b l en u m b e ro f
samples for which a large number of simulated samples
change classification. For instance the most variable
sample for Basal-like, Luminal B, Luminal A and HER2-
enriched changed in 42%, 86%, 67% and 75% of the
simulated samples, respectively. As an example, the
sample named “GEICAM_09-02639_UU” was originally
classified as HER2-enriched, but 38.7% of its simulated
samples were classified as something else. Specifically,
the simulated samples were classified as HER2-enriched
61.3% of the time, Luminal A 21.4% of the time and
Normal-like 17.3% of the time. These percentages could
be translated into probabilities that can be reported to
clinicians using a scorecard like the one depicted in Fig-
ure 4.
Conclusions
We have developed a method based on Monte Carlo
simulations and limited experimental measurements to
estimate the effect of the intrinsic experimental errors in
the measured factors contributing to MVAs. While the
specifics of the error distribution functions given in
Additional file 1 are not universal functions and they
have to be recalculated for each lab and/or experimental
setting, the method proposed here is generalizable and
can be adapted to any MVA.
Using the proposed method based on Monte Carlo
simulations and the error model described here, we
have presented data that suggests PAM50’s subtype clas-
sifications are highly reproducible on a large, indepen-
dent sample set from the GEICAM 9906 clinical trial.
We also show that there are a non-negligible number of
samples for which a significant number of the Monte
Carlo simulated samples classify differently than the par-
ent sample, indicating that the classification of the
original sample may not be reliable. To address this pro-
blem we suggest a new score card that can inform clini-
cians on the probability that a particular sample could
be classified as a different tumor subtype.
Additional material
Additional file 1: Error Distributions. Prior to performing Monte Carlo
simulations to generate simulated samples, we needed to identify the
distribution type that best models the repeated measures (error) data for
each gene. Since twelve data points for each gene were not sufficient to
identify a distribution type, data from each gene within each of the four
archetypal samples were median-centered and combined, giving forty-
seven data points per gene, since one of the archetypal Luminal A
samples failed quality control. As shown in each of the fifty plots, the
repeated measures data is most closely related to a Gaussian distribution,
given the symmetry of most genes as well as the data clustering around
a single mean value.
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final manuscript.
Sample ID: GEICAM_09-02639_UU Sample ID: GEICAM_09-02594_UU Sample ID: GEICAM_09-02588_UU
PAM50 Classification: HER2-enriched PAM50 Classification: Luminal A PAM50 Classification: Luminal B
Probability
1 to be classified as:  Probability
1 to be classified as:  Probability
1 to be classified as: 
Luminal A  Luminal A  Luminal A 
Luminal B  Luminal B  Luminal B 
HER2-enriched 	 HER2-enriched  HER2-enriched 
Basal-like  Basal-like  Basal-like 
Normal-like 
 Normal-like 
 Normal-like 
1 Probabilities are based on the classification of 100,000 Monte Carlo simulated samples of the original sample using the error model from Ebbert et al.
Figure 4 Prototype of scorecard to report uncertainty in PAM50 classification due to intrinsic experimental errors in measuring gene
expression factors using the example samples GEICAM_09-02639_UU, GEICAM_09-02594_UU and GEICAM_09-02588_UU.
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